NO328578B1 - Forbindelse samt anvendelse derav, og farmasoytisk preparat - Google Patents

Forbindelse samt anvendelse derav, og farmasoytisk preparat Download PDF

Info

Publication number: NO328578B1
Authority: NO; Norway
Prior art keywords: pharmaceutically acceptable; methyl; mammal; acceptable salt; compound according
Prior art date: 2001-05-31

Application number

NO20035201A

Other languages

English (en)

Norwegian (no)

Other versions

NO20035201L (no

NO20035201D0 (no

Inventor

Mark Edward Flanagan

Michael John Munchhof

Glenn Ernest Wilcox

Christian Koecher

Ton Rene Vries

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-31

Filing date

2003-11-24

Publication date

2010-03-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO328578(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-11-24 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-11-24 Publication of NO20035201L publication Critical patent/NO20035201L/no

2003-11-24 Publication of NO20035201D0 publication Critical patent/NO20035201D0/no

2010-03-22 Publication of NO328578B1 publication Critical patent/NO328578B1/no

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 51
239000008194 pharmaceutical composition Substances 0.000 title description 2
150000003839 salts Chemical class 0.000 claims description 36
108010019421 Janus Kinase 3 Proteins 0.000 claims description 15
102000006500 Janus Kinase 3 Human genes 0.000 claims description 15
241000124008 Mammalia Species 0.000 claims description 14
239000000825 pharmaceutical preparation Substances 0.000 claims description 14
239000003795 chemical substances by application Substances 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 10
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
239000002260 anti-inflammatory agent Substances 0.000 claims description 7
229940121363 anti-inflammatory agent Drugs 0.000 claims description 7
210000000987 immune system Anatomy 0.000 claims description 7
208000006673 asthma Diseases 0.000 claims description 6
206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
208000024827 Alzheimer disease Diseases 0.000 claims description 5
206010009900 Colitis ulcerative Diseases 0.000 claims description 5
206010012438 Dermatitis atopic Diseases 0.000 claims description 5
206010028980 Neoplasm Diseases 0.000 claims description 5
102000001253 Protein Kinase Human genes 0.000 claims description 5
201000004681 Psoriasis Diseases 0.000 claims description 5
208000024799 Thyroid disease Diseases 0.000 claims description 5
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 5
201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
201000008937 atopic dermatitis Diseases 0.000 claims description 5
230000001363 autoimmune Effects 0.000 claims description 5
201000011510 cancer Diseases 0.000 claims description 5
206010012601 diabetes mellitus Diseases 0.000 claims description 5
208000035475 disorder Diseases 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
230000005764 inhibitory process Effects 0.000 claims description 5
208000032839 leukemia Diseases 0.000 claims description 5
206010025135 lupus erythematosus Diseases 0.000 claims description 5
201000006417 multiple sclerosis Diseases 0.000 claims description 5
210000000056 organ Anatomy 0.000 claims description 5
108060006633 protein kinase Proteins 0.000 claims description 5
238000002689 xenotransplantation Methods 0.000 claims description 5
208000023275 Autoimmune disease Diseases 0.000 claims description 4
206010052779 Transplant rejections Diseases 0.000 claims description 4
201000010099 disease Diseases 0.000 claims description 4
230000002265 prevention Effects 0.000 claims description 4
125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 2
239000000203 mixture Substances 0.000 abstract description 25
238000000034 method Methods 0.000 abstract description 16
239000002904 solvent Substances 0.000 abstract description 13
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract description 6
238000002156 mixing Methods 0.000 abstract description 2
239000002244 precipitate Substances 0.000 abstract 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
239000000243 solution Substances 0.000 description 22
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
235000019441 ethanol Nutrition 0.000 description 12
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
239000007787 solid Substances 0.000 description 9
108010002350 Interleukin-2 Proteins 0.000 description 8
102000000588 Interleukin-2 Human genes 0.000 description 8
-1 alkaline earth metal salts Chemical class 0.000 description 8
239000002585 base Substances 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
239000010410 layer Substances 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 6
108010036949 Cyclosporine Proteins 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
230000001419 dependent effect Effects 0.000 description 6
239000002609 medium Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
210000001744 T-lymphocyte Anatomy 0.000 description 5
239000000443 aerosol Substances 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
238000001704 evaporation Methods 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
238000010992 reflux Methods 0.000 description 5
239000002002 slurry Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
239000002253 acid Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
230000035755 proliferation Effects 0.000 description 4
239000011734 sodium Substances 0.000 description 4
NVKDDQBZODSEIN-UHFFFAOYSA-N 1-benzyl-n,4-dimethylpiperidin-3-amine Chemical compound C1CC(C)C(NC)CN1CC1=CC=CC=C1 NVKDDQBZODSEIN-UHFFFAOYSA-N 0.000 description 3
CVQNXCBXFOIHLH-UHFFFAOYSA-N 1-benzyl-n,4-dimethylpiperidin-3-amine;dihydrochloride Chemical compound Cl.Cl.C1CC(C)C(NC)CN1CC1=CC=CC=C1 CVQNXCBXFOIHLH-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
229930105110 Cyclosporin A Natural products 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
239000002775 capsule Substances 0.000 description 3
229910002092 carbon dioxide Inorganic materials 0.000 description 3
150000001768 cations Chemical class 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
239000012458 free base Substances 0.000 description 3
150000007522 mineralic acids Chemical class 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
239000000843 powder Substances 0.000 description 3
150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
CMIBUZBMZCBCAT-HZPDHXFCSA-N (2r,3r)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HZPDHXFCSA-N 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
101710112792 Tyrosine-protein kinase JAK3 Proteins 0.000 description 2
102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
238000000065 atmospheric pressure chemical ionisation Methods 0.000 description 2
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229960001265 ciclosporin Drugs 0.000 description 2
229910052805 deuterium Inorganic materials 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
239000011707 mineral Substances 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
229940063121 neoral Drugs 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
238000010979 pH adjustment Methods 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
238000012746 preparative thin layer chromatography Methods 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
239000007921 spray Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
YSBPIVMXPQPAOS-ZBFHGGJFSA-N tert-butyl n-[3-[(3r,4r)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropyl]carbamate Chemical compound C[C@@H]1CCN(C(=O)CCNC(=O)OC(C)(C)C)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 YSBPIVMXPQPAOS-ZBFHGGJFSA-N 0.000 description 2
OZLIBRFWDOSHRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-cyanoacetate Chemical compound N#CCC(=O)ON1C(=O)CCC1=O OZLIBRFWDOSHRS-UHFFFAOYSA-N 0.000 description 1
BSSCWTYNOGTJJY-HIFRSBDPSA-N (3r,4r)-n,n-diethyl-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxamide Chemical compound C1N(C(=O)N(CC)CC)CC[C@@H](C)[C@H]1N(C)C1=NC=NC2=C1C=CN2 BSSCWTYNOGTJJY-HIFRSBDPSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
XRPCLKRQISBPHP-ZBFHGGJFSA-N 2,2-dimethyl-n-[2-[(3r,4r)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]propanamide Chemical compound C[C@@H]1CCN(S(=O)(=O)CCNC(=O)C(C)(C)C)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 XRPCLKRQISBPHP-ZBFHGGJFSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
BEOFCTTVNBUITR-ZBFHGGJFSA-N 2-methyl-n-[2-[(3r,4r)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]propanamide Chemical compound C1N(S(=O)(=O)CCNC(=O)C(C)C)CC[C@@H](C)[C@H]1N(C)C1=NC=NC2=C1C=CN2 BEOFCTTVNBUITR-ZBFHGGJFSA-N 0.000 description 1
SZEHHORUTVVESN-HIFRSBDPSA-N 2-methylpropyl (3r,4r)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidine-1-carboxylate Chemical compound C1N(C(=O)OCC(C)C)CC[C@@H](C)[C@H]1N(C)C1=NC=NC2=C1C=CN2 SZEHHORUTVVESN-HIFRSBDPSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
BPTCCCTWWAUJRK-UHFFFAOYSA-N 4-chloro-7h-pyrrolo[2,3-d]pyrimidine Chemical compound ClC1=NC=NC2=C1C=CN2 BPTCCCTWWAUJRK-UHFFFAOYSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
241000792859 Enema Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000581002 Murex Species 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
229920002302 Nylon 6,6 Polymers 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
229940092117 atgam Drugs 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000012455 biphasic mixture Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
229940107810 cellcept Drugs 0.000 description 1
238000000451 chemical ionisation Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
229960002806 daclizumab Drugs 0.000 description 1
UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
229940099364 dichlorofluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000007920 enema Substances 0.000 description 1
229940079360 enema for constipation Drugs 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
102000049912 human JAK3 Human genes 0.000 description 1
239000003906 humectant Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940073062 imuran Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
229940011051 isopropyl acetate Drugs 0.000 description 1
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
238000000021 kinase assay Methods 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
229960000681 leflunomide Drugs 0.000 description 1
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
HUXIFPWHQWBQIA-OCCSQVGLSA-N methyl n-[2-[(3r,4r)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]carbamate Chemical compound C1N(S(=O)(=O)CCNC(=O)OC)CC[C@@H](C)[C@H]1N(C)C1=NC=NC2=C1C=CN2 HUXIFPWHQWBQIA-OCCSQVGLSA-N 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
229940014456 mycophenolate Drugs 0.000 description 1
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
JSIURTDHOYZKLV-YPMHNXCESA-N n-[(3r,4r)-1-ethylsulfonyl-4-methylpiperidin-3-yl]-n-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1N(S(=O)(=O)CC)CC[C@@H](C)[C@H]1N(C)C1=NC=NC2=C1C=CN2 JSIURTDHOYZKLV-YPMHNXCESA-N 0.000 description 1
CNRBPWQNZORWRP-RISCZKNCSA-N n-[2-[(3r,4r)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-2-oxoethyl]acetamide Chemical compound C[C@@H]1CCN(C(=O)CNC(C)=O)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 CNRBPWQNZORWRP-RISCZKNCSA-N 0.000 description 1
NAYXHKZOVDRQOS-HIFRSBDPSA-N n-[2-[(3r,4r)-4-methyl-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]sulfonylethyl]propanamide Chemical compound C1N(S(=O)(=O)CCNC(=O)CC)CC[C@@H](C)[C@H]1N(C)C1=NC=NC2=C1C=CN2 NAYXHKZOVDRQOS-HIFRSBDPSA-N 0.000 description 1
URCTYVNPUZEJJF-OCCSQVGLSA-N n-methyl-n-[(3r,4r)-4-methyl-1-propylsulfonylpiperidin-3-yl]-7h-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1N(S(=O)(=O)CCC)CC[C@@H](C)[C@H]1N(C)C1=NC=NC2=C1C=CN2 URCTYVNPUZEJJF-OCCSQVGLSA-N 0.000 description 1
229960002009 naproxen Drugs 0.000 description 1
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
229940100688 oral solution Drugs 0.000 description 1
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
238000007747 plating Methods 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
235000015320 potassium carbonate Nutrition 0.000 description 1
235000011181 potassium carbonates Nutrition 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000002243 precursor Substances 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000010926 purge Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
229940063122 sandimmune Drugs 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000011664 signaling Effects 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229960001967 tacrolimus Drugs 0.000 description 1
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Hematology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Hydrogenated Pyridines (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20035201A 2001-05-31 2003-11-24 Forbindelse samt anvendelse derav, og farmasoytisk preparat NO328578B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US29477501P	2001-05-31	2001-05-31
US34104801P	2001-12-06	2001-12-06
PCT/IB2002/001905 WO2002096909A1 (en)	2001-05-31	2002-05-29	Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) -methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors

Publications (3)

Publication Number	Publication Date
NO20035201L NO20035201L (no)	2003-11-24
NO20035201D0 NO20035201D0 (no)	2003-11-24
NO328578B1 true NO328578B1 (no)	2010-03-22

Family

ID=26968730

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
NO20035201A NO328578B1 (no)	2001-05-31	2003-11-24	Forbindelse samt anvendelse derav, og farmasoytisk preparat
NO20093135A NO20093135L (no)	2001-05-31	2009-10-13	Optisk opplosning av (1-benzyl-4-metylpiperidin-3-yl) -metylamin og anvendelse derav for fremstilling av pyrrolo 2,3-pyrimidinderivater som protein kinase inhibitorer
NO2017047C NO2017047I1 (no)	2001-05-31	2017-09-08	Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
NO20093135A NO20093135L (no)	2001-05-31	2009-10-13	Optisk opplosning av (1-benzyl-4-metylpiperidin-3-yl) -metylamin og anvendelse derav for fremstilling av pyrrolo 2,3-pyrimidinderivater som protein kinase inhibitorer
NO2017047C NO2017047I1 (no)	2001-05-31	2017-09-08	Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt

Country Status (52)

Country	Link
US (2)	US7301023B2 (cs)
EP (3)	EP1666481B9 (cs)
JP (1)	JP4381137B2 (cs)
KR (5)	KR100926875B1 (cs)
CN (1)	CN1729192A (cs)
AP (1)	AP1859A (cs)
AR (2)	AR037321A1 (cs)
AT (1)	ATE519741T1 (cs)
AU (2)	AU2002304401C1 (cs)
BE (1)	BE2017C032I2 (cs)
BG (1)	BG66489B1 (cs)
BR (1)	BR0209246A (cs)
CA (1)	CA2448281C (cs)
CL (1)	CL2008000762A1 (cs)
CR (1)	CR10177A (cs)
CU (1)	CU23337B7 (cs)
CY (2)	CY1113322T1 (cs)
CZ (1)	CZ304366B6 (cs)
DK (1)	DK1666481T3 (cs)
EA (2)	EA007251B1 (cs)
EC (1)	ECSP034865A (cs)
EE (1)	EE05332B1 (cs)
ES (2)	ES2369226T3 (cs)
FR (1)	FR17C1031I2 (cs)
GE (1)	GEP20063784B (cs)
GT (2)	GT200200100AA (cs)
HR (1)	HRP20030943B1 (cs)
HU (2)	HU230876B1 (cs)
IL (1)	IL158588A0 (cs)
IS (1)	IS3023B (cs)
LT (1)	LTC1666481I2 (cs)
LU (1)	LUC00031I2 (cs)
MA (1)	MA27029A1 (cs)
MX (1)	MXPA03011062A (cs)
MY (1)	MY129649A (cs)
NL (1)	NL300887I2 (cs)
NO (3)	NO328578B1 (cs)
NZ (2)	NZ540332A (cs)
OA (1)	OA12612A (cs)
PA (1)	PA8546301A1 (cs)
PE (1)	PE20030561A1 (cs)
PL (2)	PL367945A1 (cs)
PT (1)	PT1666481E (cs)
RS (1)	RS52144B (cs)
SI (1)	SI1666481T1 (cs)
SK (2)	SK288192B6 (cs)
TN (1)	TNSN03128A1 (cs)
TW (2)	TWI316061B (cs)
UA (1)	UA80093C2 (cs)
UY (1)	UY27317A1 (cs)
WO (1)	WO2002096909A1 (cs)
ZA (1)	ZA200307982B (cs)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PA8474101A1 (es)	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
EA006227B1 (ru) *	1999-12-10	2005-10-27	Пфайзер Продактс Инк.	СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
EA006153B1 (ru) *	2000-06-26	2005-10-27	Пфайзер Продактс Инк.	СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ
PY0228255A (es)	2001-12-06	2004-06-01	Pfizer Prod Inc	Compuestos cristalinos novedosos
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
BR0313059B8 (pt)	2002-07-29	2021-07-27	Rigel Pharmaceuticals	composto, e, composição farmacêutica
ATE402700T1 (de) *	2002-08-27	2008-08-15	Merck Patent Gmbh	Glycinamid-derivate als raf-kinase-hemmer
AU2003276591A1 (en)	2002-11-26	2004-06-18	Pfizer Products Inc.	Method of treatment of transplant rejection
CN102358738A (zh)	2003-07-30	2012-02-22	里格尔药品股份有限公司	2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
MXPA06012663A (es) *	2004-05-03	2007-01-16	Novartis Ag	Combinaciones que comprenden un agonista del receptor s1p y un inhibidor de quinasa jak3.
MXPA06015237A (es)	2004-06-29	2007-12-10	Amgen Inc	Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck.
US7465726B2 (en)	2004-08-02	2008-12-16	Osi Pharmaceuticals, Inc.	Substituted pyrrolo[2.3-B]pyridines
KR20070085433A (ko) *	2004-11-24	2007-08-27	노파르티스 아게	Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물
AR054416A1 (es)	2004-12-22	2007-06-27	Incyte Corp	Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP1904457B1 (en)	2005-06-08	2017-09-06	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
KR20080026654A (ko)	2005-07-14	2008-03-25	아스텔라스세이야쿠 가부시키가이샤	헤테로시클릭 야누스 키나제 3 억제제
CN102127078A (zh)	2005-07-14	2011-07-20	安斯泰来制药株式会社	Janus激酶3的杂环类抑制剂
CN101233138A (zh) *	2005-07-29	2008-07-30	辉瑞产品公司	吡咯并[2，3-d]嘧啶衍生物、其中间体和合成方法
EP2270014A1 (en)	2005-09-22	2011-01-05	Incyte Corporation	Azepine inhibitors of janus kinases
CN103214484B (zh)	2005-12-13	2016-07-06	因塞特控股公司	作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
JP2009528295A (ja)	2006-02-24	2009-08-06	ライジェルファーマシューティカルズ，インコーポレイテッド	Ｊａｋ経路の阻害のための組成物および方法
GB0605691D0 (en) *	2006-03-21	2006-05-03	Novartis Ag	Organic Compounds
ES2415863T3 (es)	2006-12-22	2013-07-29	Incyte Corporation	Heterociclos sustituidos como inhibidores de Janus Quinasas
HUE029236T2 (en)	2007-06-13	2017-02-28	Incyte Holdings Corp	(R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
CL2008001709A1 (es)	2007-06-13	2008-11-03	Incyte Corp	Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
CA2691914C (en) *	2007-07-11	2012-06-26	Pfizer Inc.	Pharmaceutical compositions and methods of treating dry eye disorders
HUE030912T2 (en)	2008-02-15	2017-06-28	Rigel Pharmaceuticals Inc	Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
TWI444382B (zh)	2008-03-11	2014-07-11	Incyte Corp	作為ｊａｋ抑制劑之氮雜環丁烷及環丁烷衍生物
US8138339B2 (en)	2008-04-16	2012-03-20	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
MX2010011463A (es)	2008-04-16	2011-06-03	Portola Pharm Inc	2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
JP2011518219A (ja)	2008-04-22	2011-06-23	ポートラファーマシューティカルズ，インコーポレイテッド	タンパク質キナーゼの阻害剤
EP2324020A2 (en) *	2008-08-01	2011-05-25	Biocryst Pharmaceuticals, Inc.	Piperidine derivatives as jak3 inhibitors
HRP20140395T1 (hr)	2008-08-20	2014-06-06	Zoetis Llc	SPOJEVI PIROLO[2,3-d]PIRIMIDINA
JP2012517448A (ja) *	2009-02-11	2012-08-02	リアクションバイオロジーコープ．	選択的キナーゼ阻害剤
EP3026052A1 (en)	2009-04-20	2016-06-01	Auspex Pharmaceuticals, Inc.	Preparation of deuterated piperidine inhibitors of janus kinase 3
MY156727A (en)	2009-05-22	2016-03-15	Incyte Corp	N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2432472B1 (en)	2009-05-22	2019-10-02	Incyte Holdings Corporation	3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
TW201113285A (en)	2009-09-01	2011-04-16	Incyte Corp	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CA2773182A1 (en) *	2009-09-10	2011-03-17	F. Hoffmann-La Roche Ag	Inhibitors of jak
MX2012004180A (es)	2009-10-09	2012-07-17	Incyte Corp	Derivados de hidroxil, ceto y glucuronido de 3-(4-7h-pirrolo[2,3-d ]pirimidin-a-il)-1h-pirazol-1-il)-3-ciclopentilpropanonitrilo.
IN2012DN02577A (cs)	2009-10-15	2015-08-28	Pfizer
ES2461967T3 (es)	2009-12-18	2014-05-21	Pfizer Inc.	Compuestos de pirrolo[2,3-d]pirimidina
WO2011086053A1 (en) *	2010-01-12	2011-07-21	F. Hoffmann-La Roche Ag	Tricyclic heterocyclic compounds, compositions and methods of use thereof
EP2531508A1 (en)	2010-02-05	2012-12-12	Pfizer Inc.	Pyrrolo [ 2, 3 - d]pyrimidine urea compounds as jak inhibitors
EP3354652B1 (en)	2010-03-10	2020-05-06	Incyte Holdings Corporation	Piperidin-4-yl azetidine derivatives as jak1 inhibitors
AR084691A1 (es)	2010-05-21	2013-06-05	Incyte Corp	Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
EP2635557A2 (en)	2010-11-01	2013-09-11	Portola Pharmaceuticals, Inc.	Nicotinamides as jak kinase modulators
CA2818542A1 (en)	2010-11-19	2012-05-24	Incyte Corporation	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en)	2010-11-19	2012-05-24	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EP2481411A1 (en)	2011-01-27	2012-08-01	Ratiopharm GmbH	Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
EP2481397A1 (en)	2011-01-27	2012-08-01	Ratiopharm GmbH	Pharmaceutical compositions comprising tasocitinib
WO2012112847A1 (en)	2011-02-18	2012-08-23	Novartis Pharma Ag	mTOR/JAK INHIBITOR COMBINATION THERAPY
WO2012135338A1 (en)	2011-03-28	2012-10-04	Ratiopharm Gmbh	Processes for preparing tofacitinib salts
US9050342B2 (en)	2011-03-29	2015-06-09	Pfizer Inc.	Beneficial effects of combination therapy on cholesterol
CN104610264A (zh) *	2011-04-08	2015-05-13	辉瑞大药厂	结晶和非结晶形式的托法替尼,以及包含托法替尼和渗透增强剂的药物组合物
EP2524688B1 (en)	2011-05-11	2013-05-01	ratiopharm GmbH	Composition for modified release comprising ranolazine
MY165963A (en)	2011-06-20	2018-05-18	Incyte Holdings Corp	Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
CA2844507A1 (en)	2011-08-10	2013-02-14	Novartis Pharma Ag	Jak pi3k/mtor combination therapy
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
SG11201402570QA (en)	2011-11-23	2014-06-27	Portola Pharm Inc	Pyrazine kinase inhibitors
CA3131037A1 (en)	2011-11-30	2013-06-06	Emory University	Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
US10821111B2 (en)	2011-11-30	2020-11-03	Emory University	Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
EP2791141B1 (en)	2011-12-15	2017-02-08	ratiopharm GmbH	Tofacitinib mono-tartrate salt
TW201406761A (zh)	2012-05-18	2014-02-16	Incyte Corp	做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CN104837817B (zh)	2012-07-25	2017-03-22	力奇制药公司	制备3‑氨基‑哌啶化合物的合成路线
US9676756B2 (en)	2012-10-08	2017-06-13	Portola Pharmaceuticals, Inc.	Substituted pyrimidinyl kinase inhibitors
TWI761825B (zh)	2012-11-15	2022-04-21	美商英塞特控股公司	盧梭利替尼之緩釋性劑型
CN104955803B (zh) *	2012-11-30	2017-11-28	斯洛文尼亚莱柯制药股份有限公司	通过硝基‑四氢吡啶前体制备3‑氨基‑哌啶化合物
WO2014097150A1 (en)	2012-12-17	2014-06-26	Ranbaxy Laboratories Limited	Process for the preparation of tofacitinib and intermediates thereof
WO2014102826A1 (en)	2012-12-28	2014-07-03	Glenmark Pharmaceuticals Limited;	The present invention relates to process for the preparation of tofacitinib and intermediates thereof.
EP3290421B1 (en)	2013-02-22	2019-01-02	Pfizer Inc	Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak)
MX384910B (es)	2013-03-06	2025-03-14	Incyte Holdings Corp	Procesos e intermedios para hacer un inhibidor de jak.
JP6041823B2 (ja)	2013-03-16	2016-12-14	ファイザー・インク	トファシチニブの経口持続放出剤形
US20140343034A1 (en)	2013-04-25	2014-11-20	Japan Tobacco Inc.	Skin barrier function improving agent
WO2014174073A1 (en)	2013-04-26	2014-10-30	Sandoz Ag	Sustained release formulations of tofacitinib
SG11201600815WA (en)	2013-08-07	2016-03-30	Incyte Corp	Sustained release dosage forms for a jak1 inhibitor
CN104513248B (zh) *	2013-09-30	2019-05-24	重庆医药工业研究院有限责任公司	一种托法替尼中间体的纯化方法
ES2654051T3 (es)	2013-12-05	2018-02-12	Pfizer Inc.	Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas
MX362290B (es) *	2013-12-09	2019-01-10	Unichem Lab Ltd	Un proceso mejorado para la preparacion de (3r,4r)-(1-bencilo-4-me tilpiperidina-3-il)-metilamina.
CA2881262A1 (en)	2014-02-06	2015-08-06	Prabhudas Bodhuri	Solid forms of tofacitinib salts
WO2015184305A1 (en)	2014-05-30	2015-12-03	Incyte Corporation	TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
EP3180344B1 (en)	2014-08-12	2019-09-18	Pfizer Inc	Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
AU2016208906B2 (en) *	2015-01-20	2018-07-12	Wuxi Fortune Pharmaceutical Co., Ltd	JAK inhibitor
JP6687596B2 (ja)	2015-02-17	2020-04-22	アモーレパシフィックコーポレーションＡｍｏｒｅｐａｃｉｆｉｃＣｏｒｐｏｒａｔｉｏｎ	Ｎ−［４−（１−アミノエチル）−フェニル］−スルホンアミド誘導体のキラル分割方法
CN104761556B (zh) *	2015-03-21	2017-06-23	河北国龙制药有限公司	托法替布中间体杂质、托法替布杂质及其合成方法，以及托法替布的质量监控方法
EP3078665A1 (en) *	2015-04-10	2016-10-12	OLON S.p.A.	Efficient method for the preparation of tofacitinib citrate
UA119701C2 (uk)	2015-04-29	2019-07-25	Вуксі Фортуне Фармасьютікал Ко., Лтд	Піримідинові сполуки як jak-інгібітори
ES2928757T3 (es)	2015-05-01	2022-11-22	Pfizer	Acrilamidas de pirrolo[2,3-b]pirazinilo y epóxidos de las mismas como inhibidores de la Janus Quinasa
DK3305788T3 (da)	2015-05-29	2020-09-28	Wuxi Fortune Pharmaceutical Co Ltd	Janus-kinase-hæmmer
JP6507272B2 (ja) *	2015-07-27	2019-04-24	ユニケムラボラトリーズリミテッド	トファシチニブ口腔内崩壊錠
KR101771219B1 (ko) *	2015-08-21	2017-09-05	양지화학 주식회사	야누스 키나제 1 선택적 억제제 및 그 의약 용도
US10045981B2 (en)	2015-11-24	2018-08-14	Jakpharm, Llc	Selective kinase inhibitors
CN105348287A (zh) *	2015-11-30	2016-02-24	宁波立华制药有限公司	一种枸橼酸托法替布的新型合成工艺
KR102565407B1 (ko) *	2016-01-04	2023-08-10	(주)아모레퍼시픽	극성 비양자성 용매를 이용한 n-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법
US20190083609A1 (en)	2016-01-18	2019-03-21	Helmoltz Zentrum München - Deutsches Forschungszentrum Für Gesundheit And Umwelt (Gmbh)	Tofacitinib as vaccination immune modulator
KR102329162B1 (ko)	2016-06-30	2021-11-22	주식회사 대웅제약	카이네이즈 저해제로서의 피라졸로피리미딘 유도체
CN106831538B (zh) *	2017-01-22	2019-06-25	苏州楚凯药业有限公司	托法替尼中间体的制备方法
KR102398659B1 (ko)	2017-03-17	2022-05-16	주식회사 대웅제약	카이네이즈 저해제로서의 피롤로트리아진 유도체
CN107602569A (zh) *	2017-10-23	2018-01-19	上海博悦生物科技有限公司	一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途
KR102078805B1 (ko)	2017-11-30	2020-02-19	보령제약 주식회사	토파시티닙을 포함하는 약제학적 조성물
US10596161B2 (en)	2017-12-08	2020-03-24	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
KR102577242B1 (ko)	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
KR102577241B1 (ko)	2017-12-28	2023-09-11	주식회사 대웅제약	카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
PL3733673T3 (pl)	2017-12-28	2022-09-26	Daewoong Pharmaceutical Co., Ltd.	Pochodna oksyfluoropiperydyny jako inhibitor kinazy
JP7393348B2 (ja)	2018-01-30	2023-12-06	インサイト・コーポレイション	（１－（３－フルオロ－２（トリフルオロメチル）イソニコチニル）ピぺリジン―４－オン）を作製するためのプロセス及び中間体
US12161748B2 (en)	2018-01-31	2024-12-10	Twi Biotechnology, Inc.	Topical formulations comprising tofacitinib
SG11202006782YA (en) *	2018-01-31	2020-08-28	Twi Pharmaceuticals Inc	Topical formulations comprising tofacitinib
CN113768934A (zh)	2018-03-30	2021-12-10	因赛特公司	使用jak抑制剂治疗化脓性汗腺炎
KR102131107B1 (ko)	2019-01-15	2020-07-07	주식회사 다산제약	3-아미노-피페리딘 화합물의 신규한 제조 방법
NL2022471B1 (en)	2019-01-29	2020-08-18	Vationpharma B V	Solid state forms of oclacitinib
US12364696B2 (en)	2019-02-27	2025-07-22	Jak Slave Pty Ltd	Treatment of autoimmune disease
EP3938370A4 (en)	2019-03-13	2022-12-21	Intas Pharmaceuticals Ltd.	PROCESS FOR THE PREPARATION OF TOFACITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
WO2020198583A1 (en)	2019-03-27	2020-10-01	Insilico Medicine Ip Limited	Bicyclic jak inhibitors and uses thereof
US12227478B2 (en)	2019-04-05	2025-02-18	Yuhan Corporation	Processes for preparing (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine or a salt thereof and processes for preparing tofacitinib using the same
AU2020378151A1 (en)	2019-11-08	2022-05-26	Cage Bio, Inc.	Topical delivery of tofacitinib using ionic liquid
KR20220101150A (ko)	2019-11-14	2022-07-19	화이자 인코포레이티드	1-(((2s,3s,4s)-3-에틸-4-플루오로-5-옥소피롤리딘-2-일)메톡시)-7-메톡시이소퀴놀린-6-카복사마이드 조합물 및 경구 투여 형태
EP4067354B1 (en)	2019-11-25	2025-10-22	Daewoong Pharmaceutical Co., Ltd.	Novel triazolopyridine derivative and pharmaceutical composition comprising same
CA3177852A1 (en)	2020-04-04	2021-10-07	Pfizer Inc.	Methods of treating coronavirus disease 2019
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
EP4308568A1 (en) *	2021-03-15	2024-01-24	Chiesi Farmaceutici S.p.A.	Heterocyclic derivatives as janus kinase inhibitors
CN113549075B (zh) *	2021-06-23	2025-09-23	合肥华方医药科技有限公司	一种枸橼酸托法替布非对映异构体杂质的合成方法
EP4180042A1 (en)	2021-11-15	2023-05-17	Sanovel Ilac Sanayi Ve Ticaret A.S.	A film coated tablet comprising micronized tofacitinib

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL8403224A (nl)	1984-10-24	1986-05-16	Oce Andeno Bv	Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US6136595A (en)	1993-07-29	2000-10-24	St. Jude Children's Research Hospital	Jak kinases and regulations of cytokine signal transduction
US5389509A (en)	1993-10-04	1995-02-14	Eastman Kodak Company	Ultrathin high chloride tabular grain emulsions
IL112249A (en)	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
DE59500788D1 (de)	1994-05-03	1997-11-20	Ciba Geigy Ag	Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
JPH07330732A (ja) *	1994-06-10	1995-12-19	Kyorin Pharmaceut Co Ltd	光学活性な３−アミノ−１−ベンジルピペリジン誘導体
US6136596A (en) *	1995-05-19	2000-10-24	University Of Massachusetts	Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
EP0831829B1 (en)	1995-06-07	2003-08-20	Pfizer Inc.	Heterocyclic ring-fused pyrimidine derivatives
DE69618959T2 (de)	1995-07-05	2002-08-29	E.I. Du Pont De Nemours And Co., Wilmington	Pyrimidone und ihre verwendug als fungizide
EP0836605B1 (en)	1995-07-06	2002-02-06	Novartis AG	Pyrrolopyrimidines and processes for the preparation thereof
AR004010A1 (es)	1995-10-11	1998-09-30	Glaxo Group Ltd	Compuestos heterociclicos
JPH10512896A (ja)	1995-11-14	1998-12-08	フアルマシア・エ・アツプジヨン・エツセ・ピー・アー	アリールおよびヘテロアリールプリン化合物
AU1441497A (en)	1996-01-23	1997-08-20	Novartis Ag	Pyrrolopyrimidines and processes for their preparation
CH690773A5 (de)	1996-02-01	2001-01-15	Novartis Ag	Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en)	1996-02-29	1996-05-01	Pharmacia Spa	4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU1794697A (en)	1996-03-06	1997-09-22	Novartis Ag	7-alkyl-pyrrolo{2,3-d}pyrimidines
AU3176297A (en)	1996-06-25	1998-01-14	Novartis Ag	Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
EA199900021A1 (ru)	1996-07-13	1999-08-26	Глаксо, Груп Лимитед	Бициклические гетероароматические соединения в качестве ингибиторов протеинтирозинкиназы
HRP970371A2 (en)	1996-07-13	1998-08-31	Kathryn Jane Smith	Heterocyclic compounds
AU720429B2 (en)	1996-08-23	2000-06-01	Novartis Ag	Substituted pyrrolopyrimidines and processes for their preparation
CA2272705C (en)	1996-11-27	2003-03-18	Pfizer Inc.	Fused bicyclic pyrimidine derivatives
KR20000070751A (ko)	1997-02-05	2000-11-25	로즈 암스트롱, 크리스틴 에이. 트러트웨인	세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘
JP2001520748A (ja)	1997-03-24	2001-10-30	ファルマシア・アンド・アップジョン・カンパニー	Ｊａｋ２／サイトカイン受容体結合の阻害剤を同定する方法
CA2326383A1 (en)	1998-04-02	1999-10-14	Neurogen Corporation	Aminoalkyl substituted pyrrolo[2,3-b]pyridine and pyrrolo[2,3-d]pyrimidine derivatives: modulators of crf1 receptors
AU4317399A (en)	1998-05-28	1999-12-13	Parker Hughes Institute	Quinazolines for treating brain tumor
PA8474101A1 (es) *	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
PL198640B1 (pl) *	1998-06-19	2008-07-31	Pfizer Prod Inc	Związki pirolo[2,3-d]pirymidynowe, środek farmaceutyczny i zastosowanie tych związków
EP1091739A1 (en)	1998-06-30	2001-04-18	Parker Hughes Institute	Method for inhibiting c-jun expression using jak-3 inhibitors
EP1105378B1 (en)	1998-08-21	2005-03-30	Parker Hughes Institute	Quinazoline derivatives
US6080747A (en)	1999-03-05	2000-06-27	Hughes Institute	JAK-3 inhibitors for treating allergic disorders
EA006227B1 (ru) *	1999-12-10	2005-10-27	Пфайзер Продактс Инк.	СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
EA006153B1 (ru) *	2000-06-26	2005-10-27	Пфайзер Продактс Инк.	СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ
PY0228255A (es) *	2001-12-06	2004-06-01	Pfizer Prod Inc	Compuestos cristalinos novedosos
MXPA06015237A (es) *	2004-06-29	2007-12-10	Amgen Inc	Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck.

2002
- 2002-05-23 US US10/154,699 patent/US7301023B2/en not_active Expired - Lifetime
- 2002-05-29 GE GE5361A patent/GEP20063784B/en unknown
- 2002-05-29 EA EA200301193A patent/EA007251B1/ru active Protection Beyond IP Right Term
- 2002-05-29 BR BR0209246-8A patent/BR0209246A/pt not_active Application Discontinuation
- 2002-05-29 ES ES05015461T patent/ES2369226T3/es not_active Expired - Lifetime
- 2002-05-29 IL IL15858802A patent/IL158588A0/xx active IP Right Grant
- 2002-05-29 NZ NZ540332A patent/NZ540332A/en not_active IP Right Cessation
- 2002-05-29 EP EP05015454.1A patent/EP1666481B9/en not_active Expired - Lifetime
- 2002-05-29 PL PL02367945A patent/PL367945A1/xx unknown
- 2002-05-29 TN TNPCT/IB2002/001905A patent/TNSN03128A1/fr unknown
- 2002-05-29 PE PE2002000452A patent/PE20030561A1/es not_active Application Discontinuation
- 2002-05-29 KR KR1020087018519A patent/KR100926875B1/ko not_active Expired - Lifetime
- 2002-05-29 CZ CZ2003-3260A patent/CZ304366B6/cs not_active IP Right Cessation
- 2002-05-29 CN CNA028108175A patent/CN1729192A/zh active Pending
- 2002-05-29 MX MXPA03011062A patent/MXPA03011062A/es active IP Right Grant
- 2002-05-29 RS YU92303A patent/RS52144B/sr unknown
- 2002-05-29 JP JP2003500088A patent/JP4381137B2/ja not_active Expired - Lifetime
- 2002-05-29 ES ES05015454T patent/ES2393385T3/es not_active Expired - Lifetime
- 2002-05-29 KR KR1020067025590A patent/KR20060133117A/ko not_active Ceased
- 2002-05-29 HR HR20030943A patent/HRP20030943B1/xx not_active IP Right Cessation
- 2002-05-29 SI SI200231004T patent/SI1666481T1/sl unknown
- 2002-05-29 EP EP02733058A patent/EP1392694A1/en not_active Withdrawn
- 2002-05-29 AU AU2002304401A patent/AU2002304401C1/en not_active Expired
- 2002-05-29 SK SK50033-2011A patent/SK288192B6/sk active Protection Beyond IP Right Term
- 2002-05-29 KR KR1020077025832A patent/KR100868814B1/ko not_active Expired - Lifetime
- 2002-05-29 WO PCT/IB2002/001905 patent/WO2002096909A1/en not_active Ceased
- 2002-05-29 KR KR10-2003-7015681A patent/KR20040003037A/ko not_active Ceased
- 2002-05-29 NZ NZ530380A patent/NZ530380A/en not_active IP Right Cessation
- 2002-05-29 HU HUP0400152A patent/HU230876B1/hu active Protection Beyond IP Right Term
- 2002-05-29 EA EA200600575A patent/EA012666B1/ru active Protection Beyond IP Right Term
- 2002-05-29 OA OA1200300308A patent/OA12612A/en unknown
- 2002-05-29 EE EEP200300594A patent/EE05332B1/xx active Protection Beyond IP Right Term
- 2002-05-29 PT PT50154541T patent/PT1666481E/pt unknown
- 2002-05-29 CA CA002448281A patent/CA2448281C/en not_active Expired - Lifetime
- 2002-05-29 EP EP05015461A patent/EP1609781B1/en not_active Expired - Lifetime
- 2002-05-29 KR KR1020067001821A patent/KR100869409B1/ko not_active Expired - Lifetime
- 2002-05-29 TW TW092133699A patent/TWI316061B/zh not_active IP Right Cessation
- 2002-05-29 UA UA20031110841A patent/UA80093C2/uk unknown
- 2002-05-29 TW TW091111480A patent/TWI310384B/zh active
- 2002-05-29 PL PL409305A patent/PL228155B1/pl unknown
- 2002-05-29 DK DK05015454.1T patent/DK1666481T3/da active
- 2002-05-29 AT AT05015461T patent/ATE519741T1/de not_active IP Right Cessation
- 2002-05-29 SK SK1465-2003A patent/SK288199B6/sk unknown
- 2002-05-30 UY UY27317A patent/UY27317A1/es not_active Application Discontinuation
- 2002-05-30 GT GT200200100AK patent/GT200200100AA/es unknown
- 2002-05-30 AR ARP020102017A patent/AR037321A1/es not_active Application Discontinuation
- 2002-05-30 PA PA20028546301A patent/PA8546301A1/es unknown
- 2002-05-30 MY MYPI20021988A patent/MY129649A/en unknown
- 2002-05-30 GT GT200200100A patent/GT200200100A/es unknown
- 2002-05-31 AP APAP/P/2002/002550A patent/AP1859A/en active
2003
- 2003-10-13 IS IS6993A patent/IS3023B/is unknown
- 2003-10-13 CU CU20030229A patent/CU23337B7/es not_active IP Right Cessation
- 2003-10-14 ZA ZA200307982A patent/ZA200307982B/en unknown
- 2003-11-21 MA MA27410A patent/MA27029A1/fr unknown
- 2003-11-24 NO NO20035201A patent/NO328578B1/no not_active IP Right Cessation
- 2003-11-26 EC EC2003004865A patent/ECSP034865A/es unknown
- 2003-11-27 BG BG108389A patent/BG66489B1/bg unknown
2004
- 2004-05-07 AR ARP040101561A patent/AR045680A2/es unknown
- 2004-06-16 US US10/869,101 patent/US7432370B2/en not_active Expired - Lifetime
2008
- 2008-03-14 CL CL200800762A patent/CL2008000762A1/es unknown
- 2008-07-16 AU AU2008203170A patent/AU2008203170B2/en active Active
- 2008-07-24 CR CR10177A patent/CR10177A/es unknown
2009
- 2009-10-13 NO NO20093135A patent/NO20093135L/no not_active Application Discontinuation
2012
- 2012-11-09 CY CY20121101069T patent/CY1113322T1/el unknown
2017
- 2017-08-02 NL NL300887C patent/NL300887I2/nl unknown
- 2017-08-08 LT LTPA2017025C patent/LTC1666481I2/lt unknown
- 2017-08-09 LU LU00031C patent/LUC00031I2/fr unknown
- 2017-08-17 BE BE2017C032C patent/BE2017C032I2/fr unknown
- 2017-09-01 CY CY2017028C patent/CY2017028I1/el unknown
- 2017-09-04 FR FR17C1031C patent/FR17C1031I2/fr active Active
- 2017-09-08 NO NO2017047C patent/NO2017047I1/no unknown
2019
- 2019-02-19 HU HUS1900008C patent/HUS1900008I1/hu unknown

Also Published As

Publication number	Publication date
EA200301193A1 (ru)	2004-04-29
BG108389A (bg)	2005-01-31
EE200300594A (et)	2004-04-15
BG66489B1 (bg)	2015-05-29
CA2448281A1 (en)	2002-12-05
AU2008203170A1 (en)	2008-08-07
JP4381137B2 (ja)	2009-12-09
CN1729192A (zh)	2006-02-01
ES2393385T3 (es)	2012-12-20
CY1113322T1 (el)	2016-06-22
EP1666481A2 (en)	2006-06-07
IS3023B (is)	2020-08-15
EA200600575A1 (ru)	2006-08-25
WO2002096909A1 (en)	2002-12-05
KR100868814B1 (ko)	2008-11-14
JP2004534047A (ja)	2004-11-11
NL300887I2 (nl)	2017-08-31
UA80093C2 (uk)	2007-08-27
PL367945A1 (en)	2005-03-07
HRP20030943B1 (hr)	2011-11-30
BR0209246A (pt)	2004-06-15
OA12612A (en)	2006-06-09
CY2017028I2 (el)	2018-02-14
NO20035201L (no)	2003-11-24
GT200200100A (es)	2003-02-11
CL2008000762A1 (es)	2008-07-04
KR100926875B1 (ko)	2009-11-16
LUC00031I1 (cs)	2017-08-10
CU23337B7 (es)	2009-01-20
UY27317A1 (es)	2003-02-28
KR20040003037A (ko)	2004-01-07
ATE519741T1 (de)	2011-08-15
CR10177A (es)	2008-08-19
PL409305A1 (pl)	2014-12-22
SI1666481T1 (sl)	2012-11-30
GEP20063784B (en)	2006-04-10
HUS1900008I1 (hu)	2020-02-28
KR20080083028A (ko)	2008-09-12
KR20060133117A (ko)	2006-12-22
US7301023B2 (en)	2007-11-27
PL228155B1 (pl)	2018-02-28
YU92303A (sh)	2006-08-17
RS52144B (sr)	2012-08-31
LUC00031I2 (cs)	2017-10-11
FR17C1031I1 (fr)	2017-10-13
LTPA2017025I1 (lt)	2017-09-11
NZ540332A (en)	2007-05-31
BE2017C032I2 (cs)	2021-07-19
US7432370B2 (en)	2008-10-07
HUP0400152A3 (en)	2012-12-28
KR100869409B1 (ko)	2008-11-21
PE20030561A1 (es)	2003-06-23
HU230876B1 (hu)	2018-11-29
TWI310384B (en)	2009-06-01
CY2017028I1 (el)	2018-02-14
EP1666481B9 (en)	2013-05-01
DK1666481T3 (da)	2012-10-15
GT200200100AA (es)	2007-07-06
ES2369226T3 (es)	2011-11-28
FR17C1031I2 (fr)	2018-11-02
IL158588A0 (en)	2004-05-12
NO2017047I1 (no)	2017-09-08
AR037321A1 (es)	2004-11-03
SK288199B6 (sk)	2014-06-03
EP1666481B1 (en)	2012-09-19
AU2002304401C1 (en)	2009-03-05
MXPA03011062A (es)	2004-03-19
IS6993A (is)	2003-10-13
CZ304366B6 (cs)	2014-04-02
AU2002304401B2 (en)	2008-04-17
EA012666B1 (ru)	2009-12-30
NO20093135L (no)	2003-11-24
US20040229923A1 (en)	2004-11-18
EP1609781A1 (en)	2005-12-28
ZA200307982B (en)	2004-10-14
HUP0400152A2 (en)	2007-07-30
NZ530380A (en)	2005-08-26
TW200413370A (en)	2004-08-01
AU2008203170B2 (en)	2009-06-18
MA27029A1 (fr)	2004-12-20
AP2002002550A0 (en)	2002-06-30
AR045680A2 (es)	2005-11-09
EA007251B1 (ru)	2006-08-25
AP1859A (en)	2008-07-02
MY129649A (en)	2007-04-30
EP1392694A1 (en)	2004-03-03
NO20035201D0 (no)	2003-11-24
HRP20030943A2 (en)	2005-08-31
TWI316061B (en)	2009-10-21
CZ20033260A3 (en)	2004-03-17
SK288192B6 (sk)	2014-06-03
EP1609781B1 (en)	2011-08-10
TNSN03128A1 (fr)	2005-12-23
KR20060014459A (ko)	2006-02-15
CA2448281C (en)	2009-05-05
ECSP034865A (es)	2004-01-28
EE05332B1 (et)	2010-08-16
KR20080002931A (ko)	2008-01-04
EP1666481A3 (en)	2006-11-29
PA8546301A1 (es)	2003-05-14
SK14652003A3 (sk)	2004-05-04
PT1666481E (pt)	2012-12-03
LTC1666481I2 (lt)	2018-06-25
US20030073719A1 (en)	2003-04-17

Legal Events

Date

Code

Title

Description

2017-09-18

SPCF

Filing of supplementary protection certificate

Free format text: PRODUCT NAME: TOFACITINIB, EVENTUELT I FORM AV ET FARMASOEYTISK AKSEPTABELT SALT; REG. NO/DATE: EU/1/17/1178 20170322

Spc suppl protection certif: 2017047

Filing date: 20170908

2018-11-19

SPCG

Granted supplementary protection certificate